Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: Cancer Res. 2011 Oct 18;71(24):7608–7616. doi: 10.1158/0008-5472.CAN-11-1144

Figure 3. Tumor accumulation and activity of chol-anti-miR-221 in orthotopic tumor xenograft mice.

Figure 3

Tumor bearing mice were generated by injecting 1 × 106 luciferase expressing PLC/PRF/5 cells directly into the left hepatic lobe of an immunodeficient mouse. Mice that displayed sufficient bioluminescence of tumor cells (> 1 × 106 photon/sec) were dosed via tail vein injection with 3 daily doses of 30 or 60 mg/kg of chol-anti-miR-221 or cholesterol labeled scrambled control (chol-SC). Mice were sacrificed on days 4 and 7 and the endogenous miR-221 in the tumor was determined by both Northern blotting (A) and qPCR (B). (C) Tumor levels of chol-anti-miR-221 as determined by qPCR. (D) p27Kip1, p57Kip2, PTEN and β actin protein levels in the tumors of mice treated with cholesterol-labeled scrambled control oligo (chol-SC) or chol-anti-miR-221 was determined by western blotting. ** P < 0.01, Student's t-test.